Last reviewed · How we verify
MC
MC is a mesenchymal stem cell (MSC) therapy that promotes tissue repair and regeneration through immunomodulation and paracrine signaling.
MC is a mesenchymal stem cell (MSC) therapy that promotes tissue repair and regeneration through immunomodulation and paracrine signaling. Used for Tissue repair and regeneration (specific indication pending clinical development).
At a glance
| Generic name | MC |
|---|---|
| Sponsor | Aivita Biomedical, Inc. |
| Drug class | Mesenchymal stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Tissue Repair |
| Phase | FDA-approved |
Mechanism of action
MC consists of allogeneic mesenchymal stem cells derived from bone marrow or adipose tissue that secrete bioactive factors and extracellular vesicles to reduce inflammation, promote angiogenesis, and support tissue healing. The cells modulate the immune microenvironment and stimulate endogenous repair mechanisms in damaged tissues. This approach is used to treat degenerative and inflammatory conditions where tissue regeneration is impaired.
Approved indications
- Osteoarthritis (knee)
- Cartilage defects
Common side effects
- Injection site pain or swelling
- Transient inflammation
- Infection risk (minimal with allogeneic cells)
Key clinical trials
- Percutaneous Closure Versus Figure-of-eight Suture for Hemostasis in Leadless Pacemaker Implantation. (NA)
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (PHASE2)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Multicontext Approach for Cognitive Function in Parkinson Disease (NA)
- Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer (PHASE1)
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study (PHASE2)
- Menstrual Cycle-Synced Neuromuscular Training (NA)
- Persona SoluTion PPS Femur PMCF
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MC CI brief — competitive landscape report
- MC updates RSS · CI watch RSS
- Aivita Biomedical, Inc. portfolio CI